Complete Genomics Well Positioned To Move From Research To Clinical In Genome Sequencing

Rod Raynovich submits:The IPO market is setting up for continued investor interest in the biotech sector.

By Medhanie:We knew the likelihood of Complete Genomics (GNOM) remaining an independent company was low. Given its low trading price, difficulty in gaining access to capital and its pending lawsuit with Illumina (ILMN), a sale almost seems inevitable.

The Burrill Report submits: By Marie DaghlianDNA sequencing firm Complete Genomics (GNOM) went public after scaling back its deal price more than 30 percent to get it done. Shares began trading on the Nasdaq Global Market on Thursday under the symbol GNOM. The stock closed at $8.03, down more than 10 percent on the first day of trading with volume of nearly 2.5 million shares.

A teensy skeleton with a squashed alienlike head may have earthly origins, but the remains, found in the Atacama Desert a decade ago, do make for quite a medical mystery.

The Burrill Report submits: The cost of sequencing a human genome has fallen below $10,000 for the first time, a feat which has the potential to transform research costs and, eventually, therapeutic strategies.

Arrowhead Research Corporation (ARWR) Hepatitis B and ARC-520 Program Update Conference Call March 25, 2013 12:30 pm ET Executives Lauren Glaser – Investor Relations-The Trout Group Christopher Anzalone – President and Chief Executive Officer Robert Gish – Chairman-HBV Clinical Advisory Board Joan M. Block – Executive Director and Co-founder-Hepatitis B Foundation

IFM Investments Limited (CTC) Q1 2012 Earnings Call May 17, 2012 8:00 am ET Executives Donald Zhang – Co-founder, Chairman & Chief Executive Officer Harry Lu – Co-founder, Vice Chairman & President Kevin Cheng Wei – Chief Financial Officer Presentation Operator